GVHD is used primarily to prevent and treat the immune attack response to the patient's body caused by T lymphocytes in allogeneic grafts. This requires not only the prevention of the disease but also the treatment of the disease.
Immunosuppressants are the main drugs for the prevention of GVHD, but it is necessary to pay attention to the dose, duration, and possible adverse reactions, such as immunocompromise, infection, etc.
3.1 Before taking medication, it is necessary to fully understand the patient's medical history, condition, and medication history to avoid drug interactions or adverse reactions.
3.2 During the medication process, it is necessary to pay close attention to the changes in the patient's condition and adjust the treatment plan in time.
3.3 Pay attention to the preservation and use of drugs to avoid drug factors such as expiration and deterioration affecting the treatment effect.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: